
|Articles|March 15, 2004
Acuity poised to begin AMD-drug trials
Philadelphia-Acuity Pharmaceuticals has raised $2.4 million in its first institutional round of financing to fund pre-clinical studies of Cand5, being developed for treating age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Evolving glaucoma therapy: A new era of interventional strategies
2
Precision strategy: Optimizing visual outcomes with advanced small-aperture lenses
3
Throwback Series: Managing bilateral diabetic macular edema early in practice
4
ICYMI: AAO 2025 showcases new technologies and continued research
5

















































.png)


